Powered by

Basilea announces positive results of phase 3 TARGET study with antibiotic ceftobiprole in the treatment of acute bacterial skin and skin structure infections (ABSSSI)

Aug 05, 2019 - GlobeNewswire

Ceftobiprole met primary and secondary efficacy endpoints in the treatment of ABSSSICeftobiprole was well tolerated

Basel, Switzerland, August 06, 2019 Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today positive topline results for the phase 3 TARGET study, evaluating ceftobiprole in the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI).1

Dr. Marc Engelhardt, Chief Medical Officer, stated: "The successful completion and positive results of...